Vivo Bio Tech Ltd

Vivo Bio Tech Limited informed the BSE Limited that it has received a certificate from Aarthi Consultants Private Limited, its Registrar and Transfer Agent, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, pertaining to dematerialization of securities and related actions taken between July 1, 2026, and September 30, 2026.

Vivo Bio Tech Limited informed the BSE on Wednesday, September 30, 2026, that its 39th Annual General Meeting (AGM) was held via video conference, where shareholders approved the audited standalone and consolidated financial statements for the year ended March 31, 2026, and re-appointed Mr. Kalyan Ram Mangipudi, Mr. Sri Kalyan Kompella, and Dr. Sankaranarayanan Alangudi as directors, with terms extending for five consecutive years, subject to shareholder approval. The company also noted that remote e-voting commenced on September 27, 2026, and voting results will be disseminated and uploaded on the company's website and CDSL platform by October 3, 2026.

Vivo Bio Tech Limited informed the Bombay Stock Exchange that the trading window for dealing in the company's securities will be closed for all insiders, including designated persons and their immediate relatives, from October 01, 2026, until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the second quarter ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company’s internal code of conduct.

Vivo Bio Tech Limited informed the BSE on August 22, 2026, that its board approved the re-appointment of Mr. Sri Kalyan Kompella and Dr. Sankaranarayanan Alangudi as Whole-Time Directors for five-year terms, effective November 03, 2026, and January 06, 2027, respectively, pending shareholder approval, and re-appointed Mr. Kalyan Ram Mangipudi, Whole-Time Director, who retires by rotation. The company will hold its 39th Annual General Meeting on September 30, 2026, via video conferencing.

Vivo Bio Tech Limited announced that its Board of Directors approved the re-appointment of Mr. Sri Kalyan Kompella and Dr. Sankaranarayanan Alangudi as Whole-Time Directors for five-year terms, effective November 03, 2026, and January 06, 2027, respectively, pending shareholder approval. The board also approved the re-appointment of Mr. Kalyan Ram Mangipudi, who retires by rotation, and scheduled the company's 39th Annual General Meeting for September 30, 2026, to be held via video conferencing.

Net profit of Vivo Bio Tech declined 85.82% to Rs 0.19 crore in the quarter ended June 2026 as against Rs 1.34 crore during the previous quarter ended June 2025. Sales rose 14.15% to Rs 14.28 crore in the quarter ended June 2026 as against Rs 12.51 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales14.2812.51 14 OPM %35.3643.88 - PBDT3.874.12 -6 PBT0.341.48 -77 NP0.191.34 -86 Powered by Capital Market - Live

Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 13 July 2026.

Net loss of Vivo Bio Tech reported to Rs 5.16 crore in the quarter ended March 2026 as against net profit of Rs 1.06 crore during the previous quarter ended March 2025. Sales rose 15.54% to Rs 14.20 crore in the quarter ended March 2026 as against Rs 12.29 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 1.71 crore in the year ended March 2026 as against net profit of Rs 7.28 crore during the previous year ended March 2025. Sales rose 14.27% to Rs 53.33 crore in the year ended March 2026 as against Rs 46.67 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales14.2012.29 16 53.3346.67 14 OPM %31.3440.85 -39.1043.95 - PBDT3.003.49 -14 15.4417.81 -13 PBT0.251.24 -80 4.818.79 -45 NP-5.161.06 PL -1.717.28 PL Powered by Capital Market - Live

Vivo Bio Tech will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Net profit of Vivo Bio Tech rose 52.44% to Rs 1.25 crore in the quarter ended December 2025 as against Rs 0.82 crore during the previous quarter ended December 2024. Sales rose 10.65% to Rs 13.51 crore in the quarter ended December 2025 as against Rs 12.21 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales13.5112.21 11 OPM %40.6445.37 - PBDT4.233.71 14 PBT1.571.46 8 NP1.250.82 52 Powered by Capital Market - Live